The US CRO PRA International has opened a Phase I clinical trial facility in Budapest, Hungary, which will provide a "unit-on-demand" service to enhance its capabilities for early-development trials, the company said.
The US CRO PRA International has opened a Phase I clinical trial facility in Budapest, Hungary, which will provide a "unit-on-demand" service to enhance its capabilities for early-development trials, the company said.
The facility, which meets local regulatory requirements, is located in a hospital and has eight beds. The hospital provides medical treatments to various patients, and doctors can recruit from large...
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.
But the French major is still keen on early-stage M&A.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Buy boosts the French major's immunology pipeline.
Expert panel including Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.
AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.
